Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 234

1.

Biochemical interaction of anti-HCV telaprevir with the ABC transporters P-glycoprotein and breast cancer resistance protein.

Fujita Y, Noguchi K, Suzuki T, Katayama K, Sugimoto Y.

BMC Res Notes. 2013 Nov 6;6:445. doi: 10.1186/1756-0500-6-445.

2.

Telaprevir is a substrate and moderate inhibitor of P-glycoprotein, a strong inductor of ABCG2, but not an activator of PXR in vitro.

Weiss J, Becker JP, Haefeli WE.

Int J Antimicrob Agents. 2014 Feb;43(2):184-8. doi: 10.1016/j.ijantimicag.2013.10.003. Epub 2013 Nov 5.

PMID:
24332840
3.

A new intestinal cell culture model to discriminate the relative contribution of P-gp and BCRP on transport of substrates such as imatinib.

Graber-Maier A, Gutmann H, Drewe J.

Mol Pharm. 2010 Oct 4;7(5):1618-28. doi: 10.1021/mp100040f. Epub 2010 Aug 11.

PMID:
20701289
4.

Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship.

Katayama K, Masuyama K, Yoshioka S, Hasegawa H, Mitsuhashi J, Sugimoto Y.

Cancer Chemother Pharmacol. 2007 Nov;60(6):789-97. Epub 2007 Mar 8.

PMID:
17345086
5.

Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib.

Noguchi K, Kawahara H, Kaji A, Katayama K, Mitsuhashi J, Sugimoto Y.

Cancer Sci. 2009 Sep;100(9):1701-7. doi: 10.1111/j.1349-7006.2009.01213.x. Epub 2009 May 12.

6.

Pharmacological interaction with sunitinib is abolished by a germ-line mutation (1291T>C) of BCRP/ABCG2 gene.

Kawahara H, Noguchi K, Katayama K, Mitsuhashi J, Sugimoto Y.

Cancer Sci. 2010 Jun;101(6):1493-500. doi: 10.1111/j.1349-7006.2010.01539.x. Epub 2010 Feb 22.

7.

High-activity p-glycoprotein, multidrug resistance protein 2, and breast cancer resistance protein membrane vesicles prepared from transiently transfected human embryonic kidney 293-epstein-barr virus nuclear antigen cells.

Karlsson JE, Heddle C, Rozkov A, Rotticci-Mulder J, Tuvesson O, Hilgendorf C, Andersson TB.

Drug Metab Dispos. 2010 Apr;38(4):705-14. doi: 10.1124/dmd.109.028886. Epub 2010 Jan 13.

8.

Interactions of cyclosporin a with breast cancer resistance protein.

Xia CQ, Liu N, Miwa GT, Gan LS.

Drug Metab Dispos. 2007 Apr;35(4):576-82. Epub 2007 Jan 12.

9.

Computational classification models for predicting the interaction of drugs with P-glycoprotein and breast cancer resistance protein.

Erić S, Kalinić M, Ilić K, Zloh M.

SAR QSAR Environ Res. 2014;25(12):939-66. doi: 10.1080/1062936X.2014.976265. Epub 2014 Dec 1.

PMID:
25435255
10.

Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2.

Shukla S, Robey RW, Bates SE, Ambudkar SV.

Drug Metab Dispos. 2009 Feb;37(2):359-65. doi: 10.1124/dmd.108.024612. Epub 2008 Oct 29.

11.

Characterization of efflux transporters involved in distribution and disposition of apixaban.

Zhang D, He K, Herbst JJ, Kolb J, Shou W, Wang L, Balimane PV, Han YH, Gan J, Frost CE, Humphreys WG.

Drug Metab Dispos. 2013 Apr;41(4):827-35. doi: 10.1124/dmd.112.050260. Epub 2013 Feb 4.

12.

The "specific" P-glycoprotein inhibitor Tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2).

Kannan P, Telu S, Shukla S, Ambudkar SV, Pike VW, Halldin C, Gottesman MM, Innis RB, Hall MD.

ACS Chem Neurosci. 2011 Feb 16;2(2):82-9. doi: 10.1021/cn100078a. Epub 2010 Oct 21.

13.

Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters.

Weiss J, Sauer A, Divac N, Herzog M, Schwedhelm E, Böger RH, Haefeli WE, Benndorf RA.

Biopharm Drug Dispos. 2010 Mar;31(2-3):150-61. doi: 10.1002/bdd.699.

PMID:
20222053
14.

Rapid detection of ABC transporter interaction: potential utility in pharmacology.

Robey RW, Lin B, Qiu J, Chan LL, Bates SE.

J Pharmacol Toxicol Methods. 2011 May-Jun;63(3):217-22. doi: 10.1016/j.vascn.2010.11.003. Epub 2010 Nov 25.

15.

HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2).

Gupta A, Zhang Y, Unadkat JD, Mao Q.

J Pharmacol Exp Ther. 2004 Jul;310(1):334-41. Epub 2004 Mar 8.

16.

Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs.

Matsson P, Pedersen JM, Norinder U, Bergström CA, Artursson P.

Pharm Res. 2009 Aug;26(8):1816-31. doi: 10.1007/s11095-009-9896-0. Epub 2009 May 7.

PMID:
19421845
17.

In vitro characterization of axitinib interactions with human efflux and hepatic uptake transporters: implications for disposition and drug interactions.

Reyner EL, Sevidal S, West MA, Clouser-Roche A, Freiwald S, Fenner K, Ullah M, Lee CA, Smith BJ.

Drug Metab Dispos. 2013 Aug;41(8):1575-83. doi: 10.1124/dmd.113.051193. Epub 2013 May 31.

18.

Atovaquone and quinine anti-malarials inhibit ATP binding cassette transporter activity.

Rijpma SR, van den Heuvel JJ, van der Velden M, Sauerwein RW, Russel FG, Koenderink JB.

Malar J. 2014 Sep 13;13:359. doi: 10.1186/1475-2875-13-359.

19.

Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2).

Tournier N, Chevillard L, Megarbane B, Pirnay S, Scherrmann JM, Declèves X.

Int J Neuropsychopharmacol. 2010 Aug;13(7):905-15. doi: 10.1017/S1461145709990848. Epub 2009 Nov 4.

PMID:
19887017
20.
Items per page

Supplemental Content

Write to the Help Desk